cyclophosphamide + oxaliplatin + capecitabine + 5-fluorouracil + leucovorin + nab-paclitaxel + bevacizumab + avelumab + ALT-803 + aNK + ETBX-011 + GI-4000

This is an **experimental multi-agent combination regimen** composed of eleven distinct agents spanning cytotoxic chemotherapy, targeted therapy, immunotherapy (including checkpoint inhibitors, cytokine agonists, and cell therapies), and oncolytic/vaccine strategies. - **Cyclophosphamide**: Alkylating agent that crosslinks DNA, leading to apoptosis in rapidly dividing cells[5]. - **Oxaliplatin**: Platinum-based chemotherapy causing DNA crosslinking and inhibiting DNA replication[1][3]. - **Capecitabine**: Oral prodrug of 5-fluorouracil, preferentially activated in tumor cells; inhibits thymidylate synthase[3][5]. - **5-fluorouracil**: Pyrimidine analog, disrupts RNA and DNA synthesis by inhibiting thymidylate synthase. - **Leucovorin**: Stabilizes binding of 5-FU to thymidylate synthase, increasing efficacy. - **Nab-paclitaxel**: Albumin-bound paclitaxel formulation—a microtubule stabilizer resulting in mitotic arrest. - **Bevacizumab**: Humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), suppressing tumor angiogenesis and normalizing tumor vasculature[2][4]. - **Avelumab**: Fully human monoclonal antibody against programmed death-ligand 1 (PD-L1), facilitating immune checkpoint blockade. - **ALT-803**: Interleukin-15 (IL-15) superagonist; stimulates innate and adaptive immune responses. - **aNK**: Activated natural killer (NK) cell therapy; enhances cytotoxicity against tumor cells. - **ETBX-011**: Recombinant viral oncolytic vaccine targeting tumor-associated antigens. - **GI-4000**: Therapeutic cancer vaccine targeting mutated ras antigens. There is no evidence of a commercial regimen or structured clinical use of this drug combination, making it purely investigational.

Other names

XELOXXC